Humanetics Corporation to Present at Investor and Partnering Conferences
Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer
Humanetics Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis
Humanetics Corporation Publishes Positive Clinical Trial Results of BIO 300 in Patients with Non-Small Cell Lung Cancer
Humanetics Corporation Awarded Contract From Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury
Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial
MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, a clinical-stage pharmaceutical company focused on novel products to improve outcomes for patients with cancer, presented at the MedInvest Oncology Investor Conference in New York City on December 15, 2022.
Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder
MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation (Humanetics) presented data related to its new drug candidate, BIO 300, at the 68th Annual International Radiation Research Society Meeting, October 16-19, 2022. Michael Kaytor, PhD, Vice President of Research and Development for Humanetics, presented data related to BIO 300 Oral Powder, which is being developed as a medical countermeasure for use by military personnel, first responders, and at-risk civilian populations to prevent radiation damage. Protection from radiological events is of utmost importance given the current geopolitical climate.
MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation (Humanetics) announced today that it has received FDA clearance of its Investigational New Drug (IND) application for BIO 300 to mitigate erectile dysfunction in men undergoing radiation treatment for prostate cancer. This is the second IND for BIO 300 in oncology patients, and the fourth IND overall for the Company.